Puromycin Aminonucleoside: Gold-Standard Podocyte Injury and FSGS Model Agent

Executive Summary: Puromycin aminonucleoside (SKU A3740, APExBIO) is the aminonucleoside moiety of puromycin and a validated nephrotoxic agent. It induces proteinuria and glomerular lesions resembling focal segmental glomerulosclerosis (FSGS) in rat models (Meng et al., 2017). Mechanistically, it disrupts podocyte morphology, reduces cellular microvilli, and impairs glomerular filtration. Cytotoxicity is quantifiable in MDCK cell lines, with IC50 values of 48.9 ± 2.8 μM (vector) and 122.1 ± 14.5 μM (PMAT). Solubility is ≥14.45 mg/mL in DMSO and ≥29.5 mg/mL in water. These features make it essential for nephrotic syndrome and renal impairment research.

Biological Rationale

Nephrotic syndrome is a clinical condition characterized by massive proteinuria, hypoalbuminemia, and edema, often resulting from glomerular injury. Animal models are essential for elucidating the underlying mechanisms and for therapeutic development. Puromycin aminonucleoside is specifically used to induce nephrotic injury in experimental animals, notably rats, due to its reproducible ability to mimic human glomerular diseases such as FSGS (Meng et al., 2017). The compound is central to studies of podocyte function, as podocyte injury is a hallmark of proteinuric kidney diseases. By disrupting podocyte integrity, puromycin aminonucleoside provides a robust platform for studying pathways involved in proteinuria and glomerular pathology.

Mechanism of Action of Puromycin aminonucleoside

Puromycin aminonucleoside is the aminonucleoside moiety derived from the antibiotic puromycin. Its nephrotoxic effect is primarily exerted through podocyte injury. In vitro, it causes a reduction in cellular microvilli and disrupts foot-process architecture, both critical for effective glomerular filtration (Meng et al., 2017). In vivo, administration in rats leads to glomerular lesions consistent with FSGS and lipid accumulation in mesangial cells. The compound's cytotoxicity is mediated partly through transporter-mediated uptake, with increased cellular accumulation in PMAT-transfected MDCK cells, especially at acidic pH (6.6). These cellular and molecular alterations culminate in increased glomerular permeability and significant proteinuria, modeling the pathophysiology of nephrotic syndrome.

Evidence & Benchmarks

• Puromycin aminonucleoside administration in rats induces proteinuria and glomerular lesions that closely resemble human FSGS (Meng et al., 2017, https://doi.org/10.3892/or.2017.6019).
• In vitro, the compound causes marked changes in podocyte morphology, including reduced microvilli and disrupted foot-processes, confirmed via electron microscopy (Meng et al., 2017, https://doi.org/10.3892/or.2017.6019).
• Cytotoxicity in MDCK cells is quantifiable, with IC50 values of 48.9 ± 2.8 μM (vector) and 122.1 ± 14.5 μM (PMAT), supporting its suitability for transporter-uptake and toxicity assays (APExBIO, https://www.apexbt.com/puromycin-aminonucleoside.html).
• Compound solubility is ≥14.45 mg/mL in DMSO, ≥29.4 mg/mL in ethanol, and ≥29.5 mg/mL in water (with warming), facilitating diverse experimental setups (APExBIO, product page).
• Uptake is enhanced in PMAT-expressing cells, particularly at pH 6.6, enabling mechanistic studies on transporter-mediated nephrotoxicity (APExBIO, product page).

Applications, Limits & Misconceptions

Puromycin aminonucleoside is widely applied to:

• Induce nephrotic syndrome in rats for studies on proteinuria, podocyte injury, and glomerular filtration impairment.
• Model focal segmental glomerulosclerosis (FSGS) lesions and lipid accumulation in mesangial cells.
• Interrogate transporter-mediated uptake and cytotoxicity in renal cell lines.
• Test interventions targeting podocyte repair, nephrin expression, and glomerular barrier function.

This article extends the mechanistic and benchmarking focus of 'Puromycin Aminonucleoside: Benchmark Agent for Podocyte Injury' by providing explicit dose-response and solubility data under clarified experimental conditions.

For a workflow-oriented perspective, see 'Puromycin Aminonucleoside: Mechanistic Precision and Strategy', which details strategic deployment but does not enumerate transporter-specific uptake benchmarks as provided here.

Common Pitfalls or Misconceptions

• Not all nephrotic syndromes are recapitulated—puromycin aminonucleoside models FSGS and minimal change disease but not immune-complex glomerulonephritis.
• The compound’s effects are species-specific; mouse models exhibit reduced sensitivity compared to rats.
• Solubility limits and storage conditions (must be ≤ -20°C, solutions for short-term use only) are sometimes neglected, impacting reproducibility.
• It is not suitable for chronic nephropathy models requiring slow-onset injury.
• Podocyte injury does not fully represent tubulointerstitial or vascular renal pathologies.

Workflow Integration & Parameters

Dosing and Administration: Typical protocols involve intravenous or subcutaneous administration in Sprague-Dawley rats, with dosages adjusted according to experimental endpoints (e.g., 100–150 mg/kg body weight).
Solubility and Handling: Puromycin aminonucleoside is soluble at ≥14.45 mg/mL in DMSO, ≥29.4 mg/mL in ethanol, and ≥29.5 mg/mL in water with gentle warming. Always store at -20°C and use freshly prepared solutions for maximal stability.
Assay Compatibility: The compound is validated for use in cell-based cytotoxicity and transporter assays, with increased uptake at acidic pH (notably pH 6.6 in PMAT-transfected MDCK cells).
Controls and Readouts: Key endpoints include proteinuria (measured by urine protein/creatinine ratio), glomerular histology, and nephrin expression by immunostaining or western blot.
For a scenario-driven protocol guide, 'Puromycin Aminonucleoside (SKU A3740): Reliable Podocyte Injury Benchmark' details troubleshooting and assay design not fully explored in this review.

Conclusion & Outlook

Puromycin aminonucleoside remains the benchmark nephrotoxic agent for modeling podocyte injury and FSGS in preclinical nephrology. Its defined mechanism, transport specificity, and robust cytotoxicity parameters support rigor and reproducibility in renal impairment research. The compound’s versatility is enhanced by clear solubility and storage guidelines. As a product of APExBIO, puromycin aminonucleoside (SKU A3740) is recommended for laboratories seeking validated, mechanistically precise tools for nephrotic syndrome research. Future refinements may include combinatorial models to address its limitations in chronic or non-podocyte-centric renal injury.
For full technical data and ordering, see the APExBIO product page.